Earnings are set for October 29, 2026. Eli Lilly stock costs EUR 1,128.40 on October 21, 2026, down

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly (NYSE:LLY) remains in focus as healthcare innovation and pharmaceutical research continue shaping the industry.

Eli Lilly and Co. stock: Goldman lifts target to USD 1,413, falls pre-market

nbsp;Eli Lilly and Company (Lilly) and Mubadala Bio have announced

Eli Lilly (NYSE:LLY) rose during a choppy earnings week as healthcare drew a fresh bid, with booming demand for weight-management and diabetes treatments keeping the drugmaker firmly in market focus.

The new high topped the prior intraday peak of $1,292.65 set Aug. 19; shares were up about 21% year to date.

Mubadala Bio and Eli Lilly and Company (Lilly) have announced a strategic collaboration to advance the localised packaging and logistics of Lilly’s GLP-1 medicines in Abu Dhabi, marking an important step in a shared commitment to advance the emirate’s growing life sciences ecosystem.

METiS TechBio y Eli Lilly colaboran en la tecnología de administración de LNP de próxima generación, John Stanford de Incubate sobre cómo los acuerdos NMF pueden influir en las decisiones farmacéuticas futuras, y la FDA otorga aprobación acelerada a Jemperli de GSK para el cáncer de recto localmente avanzado MSI-H/dMMR.

According to The Fly, Goldman Sachs expects Lilly to beat Q3 earnings estimates and raise its outlook, citing stronger-than-expected Mounjaro growth outside the U.S. and Zepbound volume gains supported by Medicare’s GLP-1 Bridge program.

A European regulatory committee just handed Eli Lilly a potential edge over Novo Nordisk in the obesity pill race, and one key detail about how patients take the drug could tip the competitive balance.

Key TakeawaysEli Lilly shares rose 4. 6% today to a record high after Goldman Sachs raised its price target to $1,413 from $1,371 and kept its Buy rating.